These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15246161)

  • 21. FAK silencing inhibits leukemogenesis in BCR/ABL-transformed hematopoietic cells.
    Le Y; Xu L; Lu J; Fang J; Nardi V; Chai L; Silberstein LE
    Am J Hematol; 2009 May; 84(5):273-8. PubMed ID: 19358301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Altered IFNgamma signaling and preserved susceptibility to activated natural killer cell-mediated lysis of BCR/ABL targets.
    Cebo C; Voutsadakis IA; Da Rocha S; Bourhis JH; Jalil A; Azzarone B; Turhan AG; Chelbi-Alix M; Chouaib S; Caignard A
    Cancer Res; 2005 Apr; 65(7):2914-20. PubMed ID: 15805294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erythropoietin overcomes imatinib-induced apoptosis and induces erythroid differentiation in TF-1/bcr-abl cells.
    Uchida M; Watanabe T; Kunitama M; Mori M; Kikuchi S; Yoshida K; Kirito K; Nagai T; Ozawa K; Komatsu N
    Stem Cells; 2004; 22(4):609-16. PubMed ID: 15277706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression/enhanced kinase activity of BCR/ABL and altered expression of Notch1 induced acute leukemia in p210BCR/ABL transgenic mice.
    Mizuno T; Yamasaki N; Miyazaki K; Tazaki T; Koller R; Oda H; Honda ZI; Ochi M; Wolff L; Honda H
    Oncogene; 2008 May; 27(24):3465-74. PubMed ID: 18193087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
    Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase.
    Ren SY; Xue F; Feng J; Skorski T
    Exp Hematol; 2005 Oct; 33(10):1222-8. PubMed ID: 16219545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases.
    Quackenbush RC; Reuther GW; Miller JP; Courtney KD; Pear WS; Pendergast AM
    Blood; 2000 May; 95(9):2913-21. PubMed ID: 10779439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M; Nguyen TK; Dent P; Grant S
    Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
    Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
    Andreu EJ; Lledó E; Poch E; Ivorra C; Albero MP; Martínez-Climent JA; Montiel-Duarte C; Rifón J; Pérez-Calvo J; Arbona C; Prósper F; Pérez-Roger I
    Cancer Res; 2005 Apr; 65(8):3264-72. PubMed ID: 15833859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical analysis of the proapoptotic protein Par-4 in normal rat tissues.
    Boghaert ER; Sells SF; Walid AJ; Malone P; Williams NM; Weinstein MH; Strange R; Rangnekar VM
    Cell Growth Differ; 1997 Aug; 8(8):881-90. PubMed ID: 9269897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells.
    Elmaagacli AH; Koldehoff M; Peceny R; Klein-Hitpass L; Ottinger H; Beelen DW; Opalka B
    Haematologica; 2005 Mar; 90(3):326-34. PubMed ID: 15749664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nuclear topography and expression of the BCR/ABL fusion gene and its protein level influenced by cell differentiation and RNA interference.
    Bártová E; Harnicarová A; Pacherník J; Kozubek S
    Leuk Res; 2005 Aug; 29(8):901-13. PubMed ID: 15978941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression or knock-down of runt-related transcription factor 1 affects BCR-ABL-induced proliferation and migration in vitro and leukemogenesis in vivo in mice.
    Yang LJ; Yu WD; DU JB; Chao S; Chen MX; Zhao HH; Guo JZ
    Chin Med J (Engl); 2009 Feb; 122(3):331-7. PubMed ID: 19236814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of apoptosis by a dominant negative H-RAS mutant (116Y) in K562 cells.
    Sakai N; Ogiso Y; Fujita H; Watari H; Koike T; Kuzumaki N
    Exp Cell Res; 1994 Nov; 215(1):131-6. PubMed ID: 7957661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Par-4 inducible apoptosis in prostate cancer cells.
    Gurumurthy S; Rangnekar VM
    J Cell Biochem; 2004 Feb; 91(3):504-12. PubMed ID: 14755681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl.
    Hemmeryckx B; Reichert A; Watanabe M; Kaartinen V; de Jong R; Pattengale PK; Groffen J; Heisterkamp N
    Oncogene; 2002 May; 21(20):3225-31. PubMed ID: 12082638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression.
    Geay JF; Buet D; Zhang Y; Foudi A; Jarrier P; Berthebaud M; Turhan AG; Vainchenker W; Louache F
    Cancer Res; 2005 Apr; 65(7):2676-83. PubMed ID: 15805265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.